Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2022 | $19.00 | Buy | Canaccord Genuity |
| 3/10/2022 | $20.00 → $18.00 | Buy | HC Wainwright & Co. |
| 3/10/2022 | $9.00 → $10.00 | Outperform | SVB Leerink |
| 11/23/2021 | $23.00 → $19.00 | Outperform | SVB Leerink |
| 10/4/2021 | $45.00 | Buy | JonesTrading |
| 8/19/2021 | $22.00 | Outperform | SVB Leerink |
| 8/19/2021 | $22.00 | Outperform | Cowen |
| 7/27/2021 | $29.00 | Buy | H.C. Wainwright |
● Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to ra
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our comp
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the "Court") has sanctioned the scheme of arrangement providing for the proposed acquisition (the "Transaction") of Amryt by Chiesi Farmaceutici S.p.A. ("Chiesi") at a hearing held on March 31, 2023. The parties expect the closing of the Transa